We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A multicenter phase II trial of nab‐paclitaxel and capecitabine in HER‐2 negative and triple‐ negative advanced breast cancer: Could be an old regimen a valid approach to a changing disease?
- Authors
Ciccarese, Mariangela; Orlando, Laura; Fedele, Palma; Schiavone, Paola; Maiello, Evaristo; Cilenti, Giuseppina; Aieta, Michele; Bozza, Giovanni; Forcignanò, Rosachiara; Febbraro, Antonio; Bordonaro, Roberto; Romito, Sante; Rinaldi, Antonio; Borsellino, Nicolo'; Riccardi, Ferdinando; Pisconti, Salvatore; Lorusso, Vito; Colucci, Giuseppe; Surico, Giammarco; Saracino, Valeria
- Abstract
The article discusses an endocrine sensitive disease, the treatment of choice has hormonal therapy plus CDK4/6 inhibitors that proposed sequentially endocrine resistance occurs. Topics include the use of chemotherapy regimen has suggested in case of progressive disease became refractory to hormonal treatment; and presence of an endocrine sensitive disease, the treatment of choice has hormonal therapy plus CDK4/6 inhibitors has proposed endocrine resistance.
- Subjects
ITALY; ANTINEOPLASTIC agents; THERAPEUTIC use of antimetabolites; ANTIMETABOLITES; BREAST tumors; CANCER chemotherapy; CANCER patients; LONGITUDINAL method; MEDICAL cooperation; METASTASIS; PACLITAXEL; RESEARCH
- Publication
Breast Journal, 2020, Vol 26, Issue 9, p1857
- ISSN
1075-122X
- Publication type
Article
- DOI
10.1111/tbj.13856